Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure

BMC Structural Biology

Volumn 12, Issue , 2012, Pages

  Park, Jaeok ^a   Lin, Yih Shyan ^a   De Schutter, Joris W ^a   Tsantrizos, Youla S ^a   Berghuis, Albert M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; C terminal tail closure; Cancer chemotherapeutics; Farnesyl pyrophosphate synthase; Isopentenyl pyrophosphate; Mevalonate pathway

Indexed keywords

FARNESYL PYROPHOSPHATE SYNTHASE; PHOSPHATE; PYROPHOSPHATE; SYNTHETASE; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; ENZYME CONFORMATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DIPHOSPHATES; DRUG DESIGN; ENZYME INHIBITORS; GERANYLTRANSTRANSFERASE; HEMITERPENES; HUMANS; LIGANDS; MODELS, MOLECULAR; ORGANOPHOSPHORUS COMPOUNDS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; STATIC ELECTRICITY;

PYRONIA TITHONUS;

EID: 84870928035     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-12-32     Document Type: Article

References (22)

1. Isoprenylated proteins. McTaggart SJ, Cell Mol Life Sci 2006 63 255 267 10.1007/s00018-005-5298-6 16378247
2. Bisphosphonates: the first 40 years. Russell RG, Bone 2011 49 2 19 10.1016/j.bone.2011.04.022 21555003
3. Inhibition of Ras for cancer treatment: the search continues. Baines AT, Xu D, Der CJ, Future Med Chem 2011 3 1787 1808 10.4155/fmc.11.121 22004085
4. Role of Rho GTPases and their regulators in cancer progression. Rathinam R, Berrier A, Alahari SK, Front Biosci 2012 17 2561 2571
5. Rab GTPases, membrane trafficking and diseases. Li G, Curr Drug Targets 2011 12 1188 1193 10.2174/138945011795906561 21561417
6. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, et al. Cancer Res 2007 67 7450 7457 10.1158/0008-5472.CAN-07-0199 17671215
7. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Morita CT, Jin C, Sarikonda G, Wang H, Immunol Rev 2007 215 59 76 10.1111/j.1600-065X.2006.00479.x 17291279
8. Antitumor effects of bisphosphonates: from the laboratory to the clinic. Berenson JR, Curr Opin Support Palliat Care 2011 5 233 240 21825999
9. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U, Proc Natl Acad Sci USA 2006 103 7829 7834 10.1073/pnas.0601643103 16684881
10. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, et al. ChemMedChem 2006 1 267 273 10.1002/cmdc.200500059 16892359
11. Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II. Song L, Poulter CD, Proc Natl Acad Sci USA 1994 91 3044 3048 10.1073/pnas.91.8.3044 8159703
12. Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells. Lin YS, Park J, De Schutter JW, Huang XF, Berghuis AM, Sebag M, Tsantrizos YS, J Med Chem 2012 55 3201 3215 10.1021/jm201657x 22390415
13. Processing of X-ray diffraction data collected in oscillation mode. Otwinowski Z, Minor W, Methods in Enzymology Macromolecular Crystallography Part A New York: Academic Press, Charles WC, 1997 307 326
14. Coot: model-building tools for molecular graphics. Emsley P, Cowtan K, Acta Crystallogr D Biol Crystallogr 2004 60 2126 2132 10.1107/S0907444904019158 15572765
15. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. Acta Crystallogr D Biol Crystallogr 2010 66 213 221 10.1107/S0907444909052925 20124702
16. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Vagin AA, Steiner RA, Lebedev AA, Potterton L, McNicholas S, Long F, Murshudov GN, Acta Crystallogr D Biol Crystallogr 2004 60 2184 2195 10.1107/S0907444904023510 15572771
17. Regulation of product chain length by isoprenyl diphosphate synthases. Tarshis LC, Proteau PJ, Kellogg BA, Sacchettini JC, Poulter CD, Proc Natl Acad Sci USA 1996 93 15018 15023 10.1073/pnas.93.26.15018 8986756
18. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. Sanchez VM, Crespo A, Gutkind JS, Turjanski AG, J Phys Chem B 2006 110 18052 18057 10.1021/jp063099q 16956297
19. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. Marma MS, Xia Z, Stewart C, Coxon F, Dunford JE, Baron R, Kashemirov BA, Ebetino FH, Triffitt JT, Russell RG, et al. J Med Chem 2007 50 5967 5975 10.1021/jm0702884 17975902
20. Differences between bisphosphonates in binding affinities for hydroxyapatite. Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RG, J Biomed Mater Res B Appl Biomater 2010 92 149 155 19904734
21. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Jahnke W, Rondeau JM, Cotesta S, Marzinzik A, Pelle X, Geiser M, Strauss A, Gotte M, Bitsch F, Hemmig R, et al. Nat Chem Biol 2010 6 660 666 10.1038/nchembio.421 20711197
22. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls. De Schutter JW, Shaw J, Lin YS, Tsantrizos YS, Bioorg Med Chem 2012 20 5583 5591 10.1016/j.bmc.2012.07.019 22884353